RxDoctor Payments Data

Anil Rai, MD

Psychiatry · Kingston, PANPI 1306830658

Payments from drug & device makers

$3,770in general payments, 2019–2025

Across 69 payments — averaging $54.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Johnson & Johnson$546
  • Teva Pharmaceuticals USA, Inc.$497
  • E.r. Squibb & Sons, L.L.C.$473
  • Otsuka America Pharmaceutical, Inc.$367
  • Neurocrine Biosciences, Inc.$233
  • plus $590 from 7 others

What the payments were for

  • Food & beverage$3,74099%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,770 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$126,010
Medicare patients
270
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate41$123,468
Olanzapine OdtOlanzapine36$8,491
Divalproex Sodium ErDivalproex Sodium43$3,731
Clozapine42$3,599
Perphenazine33$2,844
Olanzapine73$1,671
Naloxone Hcl14$1,003
Doxepin Hcl27$603
Mirtazapine30$601
Aripiprazole13$486
Benztropine Mesylate62$466
Oxcarbazepine20$423
Trazodone Hcl71$413
Escitalopram Oxalate32$409
Buspirone Hcl23$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$546$123,46841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →